We have identified a series of novel inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase by randomly screening natural product extracts using an in vitro biochemical assay designed to identify inhibitors of integrase-catalysed strand transfer. Equisetin recovered from the fungus Fusarium heterosporum and a novel enantiomeric homologue of equisetin from Phoma sp. were isolated as inhibitors of HIV-1 integrase in vitro. Two additional analogues, a novel decalin derivative, integric acid, and oteromycin were also discovered to be inhibitors of integrase. Equisetin and related compounds inhibit 3′ endprocessing and strand transfer as well as disintegration catalysed by either the full-length enzyme or the truncated integrase core domain (amino acids 50-212). These compounds also inhibit strand transfer reactions catalysed by stable complexes assembled in vitro and integration reactions catalysed by pre-integration complexes isolated from HIV-1-infected cells. The compounds described in this report are structurally novel and mechanistically distinct from many previously described inhibitors of HIV-1 integrase. These results demonstrate the utility of using an appropriately configured assay to identify compounds that are effective post-assembly and the potential of isolating novel integrase inhibitors from complex natural product extracts.
The human immunodeficiency virus type 1 (HIV-1) enzyme integrase represents a potential target for the development of selective antiretroviral chemotherapeutic agents. Integrase is the only viral protein known to be required for the multi-step process of integration: (i) stable interaction with specific sequences within the long terminal repeat (LTR) regions at either end of the linear viral DNA (assembly); (ii) removal of the terminal two bases from each 3′ end of the viral DNA (3′ end-processing); and (iii) transfer of the 3′ ends of the viral DNA into the host cell target DNA (strand transfer) (reviewed in Brown, 1990; Farnet & Bushman, 1996; Goff, 1992) . In vivo and in vitro, the strand transfer reaction can be temporally segregated from assembly and processing of the viral DNA. In HIV-1-infected cells, integration-competent nucleoprotein complexes can persist as stable pre-integrative intermediates (Stevenson et al., 1990) . When isolated from HIVinfected cells, these pre-integration complexes (PICs) will perform integration reactions using an exogenously added target DNA substrate in vitro (Brown et al., 1987; Ellison et al., 1990; Farnet et al., 1996; Farnet & Haseltine, 1990) . Like PICs, the recombinantly expressed integrase can also be made to assemble as a stable strand transfer complex on HIV-1 LTR sequence oligonucleotides and subsequently perform the strand transfer reaction upon the addition of a target DNA substrate (Elison & Brown, 1994; Vink et al., 1994; Wolfe et al., 1996) .
Using in vitro assay systems and recombinant enzyme, a variety of inhibitors of integrase have been identified (Cushman & Sherman, 1992; Cushman et al., 1995; Fesen et al., 1993 Fesen et al., , 1994 LaFemina et al., 1995; Mazumder et al., 1995a,b; McDougall et al., 1998; Raghavan et al., 1995) . Many of these compounds are related structurally, having multiple phenolic substituents which are required for activity. Other small molecule inhibitors of integrase that have been described include nucleoside analogues, Introduction sulphonated biphenyls and diaryl sulphones, hydrazides, as well as phenanthroline metal adducts (Lipford et al., 1994; Lutzke et al., 1995; Mazumder et al., 1995b Mazumder et al., ,c, 1996 Neamati et al., 1997a,b; Zhao et al., 1997) . Although some of these inhibitors have been shown to be equally effective against virally derived integrases in both half site (single donor) and concerted, integration or full site (two donor) strand transfer reactions (Hazuda et al., 1997b) , many such compounds are ineffective against PICs isolated from HIV-infected cells (Farnet et al., 1996) . These inhibitors are also ineffective against stable strand transfer complexes assembled using the recombinant enzyme (Hazuda et al., 1997a) .
Isolation and characterization of novel human immunodeficiency virus integrase inhibitors from fungal metabolites
Since integrase is less susceptible to the effect of many inhibitors subsequent to assembly, and PICs can be longlived in HIV-1-infected cells (Stevenson et al., 1990) , it may be desirable to identify and develop compounds that are effective post-assembly. A microtitre plate strand transfer assay (Hazuda et al., 1994) previously shown to be useful for staging the reaction (Hazuda et al., 1997a) was therefore adapted to distinguish such types of inhibitors resulting from a random screening of natural product extracts. We describe the isolation and characterization of novel inhibitors of HIV-1 integrase from fungal metabolites that are among the first inhibitors of integrase to exhibit comparable activity against complexes assembled in vitro using the recombinant enzyme and PICs isolated from HIV-1-infected cells. Together with previous studies, these results illustrate the utility of using recombinant integrase in a staged reaction format as a surrogate for viral PICs in the identification and evaluation of inhibitors.
Materials and Methods

Purification of recombinant HIV-1 integrase for in vitro studies
Cloning and expression of the HIV-1 HXB2 integrase in Escherichia coli was reported earlier (Lafemina et al., 1995) . The procedure for purification of integrase was as described previously (Hazuda et al., 1994) . Briefly, cells were lysed by a combination of sonication in hypotonic buffer and the addition of lysozyme. After resuspension, the insoluable fraction was treated with DNase I and integrase was solubilized using 1 M NaCl and CHAPS (final concentration 10 mM). Following centrifugation, the supernatant was diluted 1:5 (final NaCl concentration 250 mM) and loaded onto a Heparin-agarose column equilibrated in 50 mM Tris-HCl pH 7.6, 250 mM NaCl and 10% glycerol. The column was washed extensively and integrase was eluted in the above buffer containing a final NaCl concentration of 1.0 M. The purity of the enzyme as assessed by SDS-PAGE was between 85 and 90% and enzymatic activity was demonstrated using a gel assay for 3′ processing and strand transfer as well as the microtitre strand transfer assay described below.
Microtitre plate assay for inhibition of strand transfer
High throughput assays for inhibitors of HIV-1 integrasecatalysed strand transfer were performed to identify active extracts and follow subsequent fractionation of active samples (Hazuda et al., 1994) . The assay was modified to characterize inhibitors as described (Figure 1 ; Hazuda et al., 1997b) . All reactions were performed in a final concentra- Coupled and staged strand transfer assays (Wolfe et al., 1996) were performed as outlined below.
(a) Coupled assay. The effect of inhibitors on strand transfer was assessed using blunt-ended or preprocessed donor substrates synthesized such that the terminal two nucleotides of the immobilized strand are deleted. Compounds were added just prior to the addition of integrase. After 30 min, the strand transfer reaction was initiated with the addition of the biotinylated target substrate. In this configuration both assembly and catalysis are performed in the presence of inhibitor.
(b) Strand transfer. The effect of inhibitors on strand transfer was analysed using preassembled complexes. Complexes were assembled in the absence of the inhibitors for 30 min at 37˚C using preprocessed donor substrates. Inhibitors were then added followed immediately by the biotinylated target substrate. In this configuration, only the strand transfer reaction is performed in the presence of the inhibitor.
tion of 10% DMSO. IC 50 values were determined using a series of twofold dilutions in duplicate or triplicate starting at 100 µM. Representative data from at least two independent experiments are presented. In general, the SD in these assays is ±50%.
Assays for 3′ end-processing and disintegration
The assay for specific 3′ end-processing of LTR donor sequence oligonucleotide substrates was performed as described (LaFemina et al., 1995) except that reactions included 25 mM MnCl 2 and 250 µM integrase. Disintegration reactions using a 'Y' substrate were performed according to the published method (Chow et al., 1992) . Reaction products were analysed by gel electrophoresis and were quantified by PhosphorImager analysis. All reactions were performed in a final concentration of 10% DMSO in duplicate.
Inhibition of integration by isolated PICs
PICs were isolated from HIV-1-infected cells and partially purified; inhibitors were characterized with respect to their integration activity as previously published (Farnet et al., 1996) . Integration reactions were analysed by Southern blotting and reaction products were quantified by PhosphorImager analysis. In the absence of inhibitors, integration efficiency was typically 60-90%.
Microtitre plate assays for EcoRI and DNase I activity
In the EcoRI assay, 1.25 pmol of the substrate oligonucleotide [5′-Biotin-CCCCCATGAACAGAATTCCC-CCTTACACGG-3′, 3′-GGGGGTACTTGTCTTA-AGGGGGAATGTGCC-fluorescein isothiocyanate (FITC)-5′] was immobilized in each well of a 96-well streptavidin-coated microtitre plate. Reactions (2.5 U/ml EcoRI in reaction buffer recommended by the manufacturer, Boehringer Mannheim) were performed in the presence of inhibitors or extract and 10% DMSO for 30 min at 37°C. The DNase I assay uses the above immobilized oligonucleotide substrate and DNase I (0.025 U/well; Boehringer Mannheim) incubated in integrase reaction buffer for 30 min at 37°C with inhibitor or extract. For both assays, following removal of the reaction mixture, disappearance of the immobilized substrate FITC label was monitored using an anti-fluorescein horseradish peroxidase (HRP)-conjugated antibody (NEN).
Isolation and identification of equisetin, phomasetin and integric acid
In a random screening of natural products, three fungal extracts, Fusarium heterosporum (MF6069, ATCC 74349), Phoma sp. (MF6070, ATCC 74348) and Xylaria sp. (MF6254, ATCC 74397) were determined to contain antiintegrase activity in the microtitre plate strand transfer assay. MF6069, MF6070 and MF6254 were used to prepare frozen vegetative mycelia (FVM). A portion of the agar slant was transferred aseptically to seed medium (4.0 g/l yeast extract, 8.0 g/l malt extract, 4.0 g/l glucose and 1.5 g/l polyanionic polyacrylic acid, pH adjusted to 7.0 prior to sterilization) in an unbaffled flask. The flasks were incubated on a 2 inch throw gyratory shaker at 220 r.p.m. for 2 days at 25°C and 85% relative humidity (RH). Portions of the biomass were frozen (FVM) in a final concentration of 10-15% glycerol at -75°C. FVM were used to inoculate seed cultures for isolation. Production of extracts for isolation and fractionation of the active components were conducted as described below.
Fermentation of F. heterosporum (MF6069) and Phoma sp. (MF6070)
FVM were used to inoculate seed cultures at 1.0 ml per 50 ml seed medium. The cultures were grown on a gyratory shaker (220 r.p.m.) for 2-3 days at 25°C and 85% RH; 12 ml of each seed culture was placed into 220 ml of liquid production media (medium A for MF6069 and medium B for MF6070). The contents were dispensed into a 2 l roller culture vessel containing 675 ml of steam-sterilized largeparticle vermiculite. Roller bottles were incubated horizontally, revolving at approximately 4 r.p.m. at 22°C and 75% RH for 18-19 days to obtain secondary metabolite production in the medium. 
Fermentation of Xylaria sp. (MF6254)
FVM of MF6254 (2 ml) were added to 50 ml of seed media in a 250 ml flask incubated at 25°C and 85% RH at 200 r.p.m. for 2-3 days. One ml of the seed culture was added to 35 ml of production media in a 250 ml flask and the flasks were incubated at 25°C and 85% RH at 200 r.p.m. for 24 days to obtain secondary metabolites. Seed and production media are as follows: seed medium in g/l, 5 corn steep liquor, 40 tomato paste, 10 oat flour, 10 glucose, 4 agar, 0. Bioassay-guided isolation of equisetin F. heterosporum (MF6069) fermentation broth (50 ml) was extracted with 50 ml of methyl ethyl ketone (MEK). The MEK extract, which possessed all of the integrase inhibitory activity, was concentrated to partial dryness and lyophilized to give 50 mg of a brown powder. The material was suspended in 10 ml methanol and centrifuged. The supernatant was chromatographed on a 1 l Sephadex LH-20 column eluted with methanol. Active fractions (400-450 ml of elution volume) were combined and chromatographed on a reverse-phase Zorbax RX C-8 column (20×250 mm) eluted at a flow rate of 10 ml/min, initially at 30% aqueous acetonitrile (containing 0.1% TFA) for 6 min, followed by a linear gradient of 30% to 80% aqueous acetonitrile (containing 0.1% TFA) over 40 min. Antiintegrase activity concentrated in a single peak eluting at 47-48 min. Active fractions were combined, concentrated and lyophilized to give equisetin (17 mg) as a colourless powder. The compound was homogeneous as determined by analytical HPLC (Zorbax RX C-8, 80% aqueous acetonitrile plus 0.1% TFA; flow rate 1 ml/min; t R 6.4 min). The structure of equisetin was elucidated as described (Singh et al., 1998) .
Bioassay-guided isolation of phomasetin
Phoma sp. (MF6070) fermentation broth (100 ml) was extracted with 100 ml of MEK. The MEK extract containing integrase inhibitory activity was concentrated to partial dryness and then lyophilized to give 100 mg of a brown gum. This material was dissolved in methanol (20 ml), acetone (20 ml) and methylene chloride (10 ml). The soluble portion was chromatographed on a 1 l Sephadex LH-20 column. The column was eluted with methanol and the integrase active fractions, which eluted between 400-500 ml, were combined. The combined fractions were chromatographed on a Zorbax RX C-8 (20×250 mm) column and eluted at a flow rate of 10 ml/min using a linear gradient of 30% to 80% aqueous acetonitrile (containing 0.1% TFA) over 40 min, holding at 80% aqueous acetonitrile for 15 min followed by a 10 min gradient to 100% acetonitrile. Most of the integrase inhibitory activity concentrated in a single peak eluting at 47-48 min. These fractions were concentrated and lyophilized to give a colourless powder (9 mg). Elucidation of the structure as phomasetin was determined as reported previously (Singh et al., 1998) .
Bioassay guided isolation of integric acid
A MEK extract was prepared from a 10 ml broth of the Xylaria sp. (MF6254) by shaking the broth with 10 ml MEK for 20-30 min followed by filtration. The filtrate was concentrated to dryness on a rotatory evaporator followed by lyophilization to give 50 mg of colourless solid. The solid was dissolved in 3 ml methanol and filtered. The filtrate was concentrated to 1.5 ml and injected onto a reverse phase Zorbax RX C-8 HPLC column (20×250 mm). The column was eluted at a flow rate of 8 ml/min with a 50 to 80% linear gradient of acetonitrile in water over 60 min. The compound responsible for anti-integrase activity eluted between 30-35 min and upon concentration at reduced pressure followed by lyophilization gave integric acid (17 mg) as a colourless powder. The structure elucidation and chemistry of integric acid will be reported elsewhere.
Oteromycin
Oteromycin, a modest endothelin receptor antagonist, was isolated from two strains of the same unidentified fungus (MF5810, ATCC 74201 and MF5811, ATCC 74202) (Singh et al., 1995) .
Results
Isolation and identification of integric acid, equisetin and phomasetin as novel inhibitors of HIV-1 integrase
Using recombinantly expressed HIV-1 integrase, an in vitro biochemical assay that recapitulates the staged process of integration was designed and implemented as a screen for inhibitors ( Figure 1a) ; a detailed description of the general technique has been published previously (Hazuda et al., 1994) . The strand transfer assay is performed directly in microtitre wells covalently coated with a synthetic HIV-1 LTR sequence oligonucleotide donor substrate. Integrase forms a stable complex with the immmobilized donor substrate and processes the 3′ end in preparation for the subsequent strand transfer reaction (Wolfe et al., 1996) . A heterologous oligonucleotide biotinylated on each 3′ end is then provided as the target substrate. Integrase covalently links the biotinylated target oligonucleotide to the immobilized donor substrate and the product of the reaction is quantified using a colorimetic avidin-linked alkaline phosphatase reporter.
Using this assay, several natural product extracts including fermentation products of the fungi F. heterosporum, Phoma sp. and Xylaria sp. were identified as containing one or more component(s) inhibitory to the activity of integrase in vitro. These extracts were selective for integrase with respect to one or more unrelated endonucleolytic enzymes assayed under identical conditions (including concentration of substrate and divalent cation cofactor, e.g. DNase I and EcoRI, data not shown). Large-scale production of the fermentation products was performed and the inhibitory component(s) in these extracts were purified using a combination of size-exclusion column chromatography and reverse-phase HPLC as detailed in Materials and Methods. The microtitre strand transfer assay was used to guide the isolation and follow inhibitory activity subsequent to fractionation. The structure of each compound was determined by spectroscopic analysis (Singh et al., 1998) . The purity of each compound was >98% as determined by analytical HPLC and 1 H NMR. From each of the three fungal extracts fractionated, a unique inhibitor of HIV-1 integrase was isolated. The active component from the MEK extraction of the fungus F. heterosporum was identified as equisetin. Not previously identified as an inhibitor of integrase, equisetin is a known natural product previously described as an inhibitor of mitochondrial ATPases (Koenig et al., 1993) . The characterization of the active components from two other fungal species, Phoma sp and Xylaria sp, yielded two novel compounds, phomasetin and integric acid, respectively, both of which are related to equisetin. The structures of these three inhibitors and an additional analogue, oteromycin previously isolated as an endothelin antagonist from an unrelated fungal extract (Singh et al., 1995) are shown in Table 1 along with a summary of their respective activities against HIV-1 integrase.
Integric acid, equisetin, phomasetin and oteromycin are structural homologues that comprise a novel and structurally unique class of integrase inhibitors. Equisetin and the enantiomeric homologue phomasetin possess two distinct structural halves, an upper tetramic acid type hydrophilic half and a lower hydrophobic bicyclic (transdecalin) half. Phomasetin has an additional olefinic methyl group in the decalin half and the side chain is extended by an extra olefin. Integric acid and oteromycin also possess a trans-decalin system. Oteromycin is more analogous to equisetin with the ketone missing in the five membered ring; however, integric acid has an overall negative charge and the carboxylic acid group could be functionally homologous to the tetramic acid unit of both equisetin and phomasetin. Despite certain structural differences, as outlined below, the activities of each of these compounds against HIV-1 integrase are comparable (Table 1) . Although the similarities in the biochemical activities of equisetin and phomasetin may be surprising considering the enantiomeric nature of these compounds, the anti-integrase activity cannot be explained solely on the basis of the upper tetramic acid moiety, given that simple acyl tetramic acids are inactive (data now shown).
Integric acid and equisetin inhibit reactions catalysed by the full-length recombinant and truncated integase proteins
The entire process of integration requires assembly of integrase as a stable complex on the LTR donor substrate, followed by two catalytic reactions, 3′ end processing and strand transfer. To address whether one or both of these reactions is affected by integric acid or equisetin (the two most active compounds) we (i) circumvented the requirement for end processing in the strand transfer assay by using preprocessed donor substrates; and (ii) directly assessed 3′ end processing activity using a radiolabelled 20 bp oligonucleotide donor substrate and analysing the 18 bp N-2 reaction product on sequencing gels (LaFemina et al., 1995) . We also examined the disintegration activity of integrase using a 'Y' substrate which mimics the reaction intermediate of strand transfer wherein the donor DNA is linked on one strand to a nicked target substrate. As described previously, integrase will catalyse the removal of the donor DNA as well as relinkage of the nicked target sequence (Chow et al., 1992) . In this study, release of the donor sequence was monitored subsequent to analysis of the reaction on sequencing gels.
As summarized in Table 1 , the activity of both integric acid and equisetin in 3′ end processing, strand transfer and disintegration were similar in all assays, 5-10 µM for integric acid and 15-25 µM for equisetin. No significant difference in the activity of integric acid or equisetin was detected in the strand transfer assay when either preprocessed or blunt-ended donor substrates were used (Figure 1a ). Both compounds were also inhibitory in the 3′ end processing assay as demonstrated by a dose-dependent decrease in the relative amount of the specific N-2 18 nucleotide product in response to increasing concentration of inhibitor. In addition, integric acid and equisetin were observed to inhibit 3′ end processing when manganese or magnesium was used as the cofactor in the reaction (data not shown). Integric acid and equisetin also inhibited disintegration mediated by both the full-length enzyme and the catalytic core domain, amino acids 50-212 (Table 1) . The latter result suggests a direct interaction between this class of inhibitors and the catalytic core of integrase. This result may not be surprising since equisetin was previously identified as an ATPase inhibitor and ATP analogues have been show to crosslink at high concentrations to the integrase core region (Drake et al., 1998) .
Integric acid and equisetin inhibit reactions catalysed by isolated HIV-1 PICs and strand transfer complexes assembled in vitro Each of the previously described assays are 'coupled' reactions, requiring that integrase first assembles appropriately on a given substrate and then mediates the catalytic reaction. However, many inhibitors of HIV-1 integrase do not affect 'uncoupled' reactions, enzymatic reactions catalysed by preassembled complexes. Once assembled as a stable complex on the donor substrate, the 3′ end processing and strand transfer reactions catalysed by the recombinant enzyme are resistant to many compounds that are relatively potent inhibitors in coupled assays (Hazuda et al., 1997a) . Integration reactions catalysed by PICs isolated from HIV-1-infected cells are also unaffected by many of the same compounds (Farnet et al., 1996) . We therefore examined whether equisetin and related compounds are mechanistically similar to previously identified inhibitors with respect to their effect on the catalytic activity of stable complexes assembled in vitro using recombinant enzyme as well as partially purified HIV-1 PICs from infected cells.
To analyse the effect on strand transfer catalysed by preassembled complexes using recombinantly expressed enzyme, the reaction was staged as outlined in Figure 1(b) . Integrase complexes were assembled on immobilized preprocessed donor substrates in the absence of inhibitor and compounds were added immediately prior to the addition of the target DNA substrate. The strand transfer reaction was performed at 37°C for 30 min in the presence of the inhibitor and the reaction products were quantified as above. For each of the four compounds, comparing the results of the coupled and staged preassembled strand transfer assays, inhibition of strand transfer activity was only slightly diminished (two to threefold) relative to the coupled assay when integrase donor substrate complexes were preassembled prior to the addition of the inhibitor (Table 1 ). These results are strikingly different from those obtained in similar studies of other integrase inhibitors where potency decreases dramatically subsequent to assembly (Hazuda et al., 1997c) .
In combination with the observation that integric acid and related compounds effectively inhibit catalysis postassembly, integric acid and equisetin also inhibit integration reactions catalysed by stable PICs isolated from HIV-1-infected cells. As shown in Table 2 , integric acid and equisetin inhibited PICs with IC 50 values of 25-30 µM. In both cases, the relative activities of these inhibitors versus the virally derived material was similar to their activity in in vitro strand transfer reactions using preassembled complexes and the recombinant enzyme (Table 2) . Equisetin and the novel homologues identified in this report are therefore, as a class, distinct from many other integrase inhibitors described to date which are significantly less effective or virtually inactive in inhibiting the catalytic activities of stable complexes formed in vitro (Fesen et al., 1994; Hazuda et al., 1997c) or isolated PICs assembled in vivo (Farnet et al., 1996) .
Discussion
We have described the isolation and biochemical characterization of several novel inhibitors of HIV-1 integrase from natural product extracts. The compounds described (Farnet et al., 1996) .
herein and the data presented demonstrate that integric acid, equisetin, phomasetin and oteromycin comprise a unique class of compounds different both structurally and functionally from many integrase inhibitors previously described. Although these inhibitors do not have sufficient potency to produce significant antiviral activity against HIV-1 in cell culture, the ability to isolate novel and mechanistically interesting structures from complex mixtures illustrates the utility of screening inhibitors of integrase using a high throughput assay to evaluate natural product extracts. These studies also demonstrate that the recombinant enzyme and appropriately configured assay systems can reflect the ability of integrase inhibitors to affect biochemical processes mediated by viral PICs. Therefore, high throughput screens employing in vitro assays systems such as the one used for these studies have the potential to identify biologically relevant inhibitors of HIV-1 integrase.
